On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > BUSINESS
BUSINESS
- South Korea OKs Lenvima for 1st Line HCC: Eisai
August 30, 2018
- Eisai/Biogen’s Alzheimer’s Drug Aducanumab Shows Continued Efficacy in Long-Term Extension PIb Study
August 30, 2018
- Imfinzi, Gazyva Now Available in Japan
August 30, 2018
- Celltrion Launches Herceptin Biosimilar in Japan
August 29, 2018
- Ono Hooks Up with BMS, Clovis to Develop Opdivo/Rucaparib Combo Therapy in Japan, S. Korea, Taiwan
August 29, 2018
- I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
August 28, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- New AG Re-Pricing Rule Erodes 10 Billion Yen from Daiichi Sankyo Espha Sales
August 28, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
- Opdivo Price Cut Won’t Have Much Impact on Financial Results: Ono
August 27, 2018
- Pfizer, Astellas Move UP Completion Dates for 2 Xtandi Studies
August 24, 2018
- Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
August 24, 2018
- Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
August 24, 2018
- Lenvima Approved for 1st Line HCC Use in Europe: Eisai/Merck
August 24, 2018
- Shire Japan, Medipal Introduce Emergency Delivery System for Hemophilia Treatment
August 23, 2018
- MSD Launches Antibacterial Agent Sivextro
August 23, 2018
- Takeda, Ono Join Hands in Japan PIII for Opdivo-Cabozantinib Combo
August 23, 2018
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- Otsuka Grabs Rights to Osaka Univ. CAR-T Therapy
August 22, 2018
- Daiichi Sankyo Espha Unveils Authorized Generic Pact with AstraZeneca, 3 More Oncology AGs Pending Approval
August 21, 2018
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…